Dubai Healthcare City has approved the sale and distribution of a new vaccine therapy for ovarian cancer.
CVac, which is produced by the Australian biotechnology Prima BioMed, is expected to be available before the end of 2011, the firm has said.
Prima, who last week raised $40.4m for the development of the drug, plans to use the Dubai deal as a springboard for its distribution throughout the Middle East. The firm, which is aiming to take a 10-25 percent share of the ovarian cancer treatment market globally, estimates this region’s market at around $517m.
“This represents an important pilot commercialisation program for CVac. We also have the potential to extend the application of CVac in Dubai to other mucin-1 positive tumours, which is another exciting opportunity for the company,” Dr Neil Frazer, chief medical officer at Prima Biomed,” said in a statement.
The Cvac cancer vaccine approach stimulates the patient's own immune system to target and destroy tumours.
The vaccine is administered after surgery and chemotherapy.
Prima is ramping up its expansion plans and is looking for approval in the US, Europe and Australia.For all the latest health tips & news from the UAE and Gulf countries, follow us on Twitter and Linkedin, like us on Facebook and subscribe to our YouTube page, which is updated daily.
Subscribe to Arabian Business' newsletter to receive the latest breaking news and business stories in Dubai,the UAE and the GCC straight to your inbox.